logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Tag: Acceleron Pharma (XLRN)

Stories about research, clinical trials results and an FDA ruling

The Week in Review #26 IN THE BIOTECH WORLD -  RESEARCH -  IMPROVING CRISPR GENE EDITING The problem cited with gene editing is that the editing may stay switched on after it succeeded in reaching its goals. To prevent further...

Read More

July 9, 2018

0

Stories about research, clinical trials results and an FDA ruling

The Week in Review #26 IN THE BIOTECH WORLD -  RESEARCH -  IMPROVING CRISPR GENE EDITING The problem cited with gene editing is that the editing may stay switched on after it succeeded in reaching its goals. To prevent further...

Read More

July 9, 2018

0

Another Approval for Celgene and the First for Acceleron

FDA Approval for Celgene and Acceleron Drug REBLOZYL® The U.S. Food and Drug Administration ( FDA ) has approved Celgene’s ( CELG ) and Acceleron Pharma’s ( XLRN )  drug  REBLOZYL®  (luspatercept-aamt) for anemia only in adult patients with beta...

Read More

November 12, 2019

0

Stories about research, clinical trials results and an FDA ruling

The Week in Review #26 IN THE BIOTECH WORLD -  RESEARCH -  IMPROVING CRISPR GENE EDITING The problem cited with gene editing is that the editing may stay switched on after it succeeded in reaching its goals. To prevent further...

Read More

July 9, 2018

0

Another Approval for Celgene and the First for Acceleron

FDA Approval for Celgene and Acceleron Drug REBLOZYL® The U.S. Food and Drug Administration ( FDA ) has approved Celgene’s ( CELG ) and Acceleron Pharma’s ( XLRN )  drug  REBLOZYL®  (luspatercept-aamt) for anemia only in adult patients with beta...

Read More

November 12, 2019

0

Another Approval for Celgene and the First for Acceleron

FDA Approval for Celgene and Acceleron Drug REBLOZYL® The U.S. Food and Drug Administration ( FDA ) has approved Celgene’s ( CELG ) and Acceleron Pharma’s ( XLRN )  drug  REBLOZYL®  (luspatercept-aamt) for anemia only in adult patients with beta...

Read More

November 12, 2019

0

  • 1

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy